INTRODUCTION
============

Genes encoding the membrane protein, one of the largest gene groups in human and mouse genome, are claimed to be more than 10% of genes encoding all genes \[[@ref1]\]. Solute carriers (SLCs) proteins, one of the major sub-groups of membrane proteins that control the transport of exceptional substances such as sugar, amino acids, nucleotides, inorganic ions, lipids, and drugs on the cell membrane, include more than 400 different membrane- spanning SLCs organized with 65 families in the human \[[@ref2]\]. Many of these membrane proteins act as coupled symporters (co-transporters) using downhill ion (H^＋^ or Na^＋^) gradients as a pushing force to transport the substrate to cells against the concentration gradient \[[@ref3]\].

The transported molecule moves towards the low concentration region through the membrane and reaches equilibrium. Other members of the SLC family function as antiporters with substrate-binding sites, while the remaining members show channel-like properties. It is known that ion exchangers cause pH alterations around the cell surface. Therefore, when combined with Na^＋^/K^＋^ ATPase, they negate the load balance by making the intracellular membrane potentially negative. The transition of the molecule through membranes is facilitated either by changing load balance or pH \[[@ref4]\]. In SLC family neurons, the neurotransmitter is considered to be neurodegenerative disorders such as schizophrenia (GABA, GLYT, and SERT), epilepsy (GABA and BGT), anxiety (GABA and SERT), depression (SERT and NAT), and Parkinson disease (DAT), amyotrophic lateral sclerosis (GLT) \[[@ref5]\]. In particular, irregularities in SLC polymorphism play role in the mechanism of neurological and neuropsychiatric disorders by altering transport expression, malfunction, and regulation in the neurotransmitter system ([Fig. 1](#F1){ref-type="fig"}).

SOLUTE CARIERS' TRANSPORTER FAMILY
==================================

The localization of SLC proteins in the brain is shown in [Table 1](#T1){ref-type="table"}. neurotransmitters in the brain that are released into the synapse are taken back to presynaptic neurons via SLC1 and 6 carriers \[[@ref2]\]. SLC1 family has two subfamilies that encode glutamate transporters (SLC1A1, 2, 3, 6, and k) and neutral aminoacid transporters (SLC1A4 and 5). SLC2 members like 1, 2, 3, 6, 8, 10, and 13 are expressed in the brain. SLC5 human genes encoding SGLT proteins with the exception of SLC5A4, 5, and 7 are all expressed in the brain \[[@ref6],[@ref7]\]. SLCA1-7 human genes are members of the high-affinity glutamate and neutral amino acid transporter family. SLC1A5 and 7 are known not to show any expression in the human brain. SLC1A1 encodes glutamate carrier called EAAC1 (also known as EAAT3). EAAC1 is a neuronal type-high affinity glutamate carrier. They are predominantly expressed in neurons in various brain regions, particularly in the hippocampus, cerebral cortex, striatum, superior colliculus, and thalamus \[[@ref8]\]. Studies on EAAC1 knock-out mice showed no improvement in neurological symptoms and neurodegeneration \[[@ref9]\]. Besides, significant low spontaneous locomotor activity was found in homozygous mutants of knock-out mice \[[@ref9]\]. SLC1A2 encodes glial type-high affinity glutamate transporter which is called glial glutamate transporter and glutamate synthase (GLT1) (also known as an excitatory amino acid carrier, EAAT2). This multi-pass membrane protein is required to terminate the postsynaptic effect of glutamate by rapidly removing glutamate release from the synaptic cleft, as well as preserves glutamate concentrations below toxic concentrations to prevent neuronal damage \[[@ref10]\]. EAAT2 is particularly expressed in the cortex, hippocampus, and astrocytes of various brain regions. In the histological analysis, GLT1 knock-out mice showed neuronal degeneration in the hippocampal CA1 region, indicating the neuroprotective role of GLT1 \[[@ref9]\]. It has also been reported that GLT1 knock-out mice have similar behavioral patterns and dramatic fatal spontaneous epileptic seizures as N-methyl-D-aspartate (NMDA)-induced seizures \[[@ref11]\]. SLC1A3, also known as EAAT1, encodes glutamate GLAST. is a glial type-high affinity glutamate carrier which is especially seen in cerebellum \[[@ref9]\]. While GLAST knock-out mice can coordinate simple movements, it is reported that in more difficult movement dysfunction occurs in parallel with the abnormality in cerebellum \[[@ref9]\]. SLC1A4 encodes the Na^＋^ dependent neutral amino acid carrier ASCT1 (also known as SATT) \[[@ref12],[@ref13]\]. In the brain, ASCT1 is preferably expressed in glial cells with L-serine biosynthetic enzyme 3-phosphoglycerate dehydrogenase. Therefore, large amounts of L-serine are synthesized and stored in glial cells. The L-serine release is achieved by changing the structure of the extracellular substrate due to alterations in ASCT1. This change assumes that neurons will meet their metabolic needs through the transport of small glial born neutral amino acids \[[@ref14]\]. This change assumes that neurons will meet their metabolic needs through the transport of small glial born neutral amino acids. ASCT1 shows a broad expression in the brain. SLC1A5 encodes a second isoform of the ASC transport system called ASCT2 (also known as AAAT). ASCT2 carries glutamate with low affinity and ASCT2 mediated glutamate transport increases at low pH \[[@ref15]\]. Similar to ASCT1, ASCT2 mediates Na^＋^ dependent mandatory substrate amino acid change \[[@ref16]\]. SLC1A6 encodes the neuronal high-affinity glutamate transporter EAAT4, which is expressed in purkinje cells in the cerebellum, mainly on postsynaptic dendritic spines \[[@ref17],[@ref18]\]. The SLC1A7 gene encodes the EAAT5 protein and the members of the SLC4 family such as 3, 4, 7, 8, and 10 are distributed in the brain. They have a role in bipolar disorder through Li^＋^ channels in epilepsy by affecting GABA and chloride channels \[[@ref19],[@ref20]\].

All SLC6 are also referred to as neurotransmitter transporters. These transporters provide regulation of neurotransmitter homeostasis in the central nervous system (CNS) \[[@ref21]\]. SLC6 family transporters are known to make a balance between inhibitory neurotransmitters, GABA and glycine, and excitatory neurotransmitter glutamate.

Many subtypes of the SLC7 gene family are expressed in the brain. Particularly, they play an important role in diseases like schizophrenia and Parkinson's disease (PD) by influencing the distribution of the amine or amino acid structured neurotransmitter precursor known as L-DOPA \[[@ref22],[@ref23]\].

The SLC11 (NRAMP) family members catalyze the passage of metal ions like Fe^2＋^ through the cell membrane. Fe^2＋^ is really important for the development of the brain and takes place in many important functions such as neurotransmission and myelination. Fe^2＋^ deficiency during development may have a significant negative impact on brain development and cognition that may lead to a chronic neurological disorder. On the other hand, abnormal levels of Fe^2＋^ have been reported in brain regions in neurodegenerative diseases like PD, Hallervorden-Spatz syndrome, Huntington disease (HD) and Alzheimer disease (AD) \[[@ref24],[@ref25]\]. SLC11A2 mediated Fe^2＋^ transport has been suggested to be involved in neuronal degeneration in PD and AD \[[@ref26],[@ref27]\].

The family of SLC12 chloride carriers contributes to ion currents in various tissues, especially in the brain, kidney and choroid plexus. Seven of the 9 members of this family are well known. Na^＋^: K^＋^: 2Cl^−^ cotransporter 1 (NKCC1) is really important for the function of both central and peripheral nervous systems. The activity of NKCC1 helps to protect the extracellular areas of the brain and the environment of cerebrospinal fluid. NKCC1 expression in neurons is regulated by low expression in mature neurons and high in immature neurons. In the adult peripheral nervous system, NKCC1 is intensely expressed in primary sensory neurons and root ganglia. Although K^＋^: Cl^−^ cotransporter (KCC) 1, KCC3 and low levels of KCC4 is expressed in the brain, their expression is not limited to the nervous system, as opposed to the neuronal-specific KCC2. KCCs have been associated with sickle cell anemia, cancer growth and as well as neurological diseases. KCC2 expression is high in the hippocampus, cerebellum, and brain stem neurons \[[@ref28]\]. Among the members of the SLC superfamily, organic anion transporting polypeptide plays an important role in the transport of both endo-xenobiotics, including numerous drugs throughout the superfamily (OATPs) plasma membranes \[[@ref29]\]. It is known that there are eleven OATPs in humans. On this basis, human and rodent OATPs are composed of 6 families (OATP1-6) and each family may have sub-families such as OATP1A, OATP1B, OATP1C. Expressions of OATPs have generally been identified in epithelial or endothelial cells of each organ and some OATPs such as OATP1C1 specific to the rat brain have limited expression in other specific organs. Commonly expressed OATP2A1, OATP3A1 and OATP4A1 were determined by mRNA in all tissues in human \[[@ref29],[@ref30]\]. OATP1C1, a member of the OATP1 family, is expressed in glial cells throughout the hypothalamus. Moreover, prostaglandin transporter OATP2A1 is one of the ubiquitous OATP which is known to be expressed in neurons, astrocytes, epithelial and endothelial cell layers \[[@ref30]\]. OATP3A1, which is localized in neuron and frontal cortex, has the highest expression level in the brain and also found in many tissues. Expression of OATP5A1 and OATP6A1 in the brain were determined with mRNA analysis \[[@ref29]\].

Organic cation transporter 3 (OCT3) encoded by SLC22A3 and SCL6A4 encoded serotonin transporter (SERT) has a high and low affinity, respectively during serotonin transport \[[@ref31]\]. In SERT knock-out mice, the transcription level of SLC22A3 increased in the hippocampus and no such change was determined in other brain regions \[[@ref32]\]. This regulation of SLC22A3 plays an important role in the recruitment of serotonin in the absence of SLC6A4 and may fully obscure the in vivo effect of SERT.

SLC25 proteins that act as carriers of a wide variety of molecules, are the largest SLC family with 46 members (SLC25A1-46) known as mitochondrial carriers \[[@ref33]\]. The most of the SLCs are highly expressed in brain regions such as hypothalamus, pituitary, hippocampus, thalamus, amygdala, and brainstem, but are also present intensely in the periphery \[[@ref34]-[@ref38]\]. These proteins have been reported to play a vital role in neuronal signaling for energy production in healthy neurons \[[@ref39]\].

In humans, there are two important Zn^2＋^ carrier family known as SLC30 (ZnT) and SLC39 (ZIP) family which provide cellular Zn^2＋^ homeostasis. The SLC39 contains 14 members and they are the transmembrane carriers which pump the extracellular Zn^2＋^ and Cu^2＋^ into the cell. Additionally, recent studies have showed that ZIP family proteins have important role in Fe^2＋^ transport \[[@ref40]\]. Zn^2＋^ and Cu^2＋^ play an important role in vital biological processes like growth, development and neuron functions. SLC30A3 transfers Zn^2＋^ to synaptic vesicles in the brain. Interestingly, SLC30A3 expression in the brain is independent of the availability of dietary Zn^2＋^ and may be important in conservation of brain Zn^2＋^ during Zn^2＋^ deficiency. However, the expression of SLC30A3 decreases with aging, and this process progresses faster in patients suffering from neurodegenerative AD \[[@ref41],[@ref42]\]. Thus, it seems likely that a loss of synaptic accumulation and subsequent release of Zn^2＋^ play a role in AD pathogenesis \[[@ref41]\]. Increased expression of SLC30A1, SLC30A4, and SLC30A6 was observed in AD patients. Chronic perturbation of Cu^2＋^ homeostasis causes neuronal degeneration \[[@ref43]\]. Microglia has been shown to upregulate SLC31A1 in response to interferon-g activation. Increased Cu^2＋^ uptake and trafficking by microglia may have a neuroprotective role in AD \[[@ref27]\].

Among the Mg^2＋^ carriers, SLC family 41 (SLC 41) has three members known as A1, A2 and A3. Although SLC41 is distributed in various tissues and organs, it is expressed in brain and provides Na^＋^/Mg^2＋^ activity. Na^＋^/Mg^2＋^ activity is obvious in various avian and mammalian cell types like hepatocytes, neurons and glial cells. Degradation or irregularity of Na^＋^/Mg^2＋^ exchanger may alter the systemic and intracellular Mg^2＋^ homeostasis and participate in the pathogenesis of various diseases related to hypertension, ischemic heart disease, neurodegeneration, inflammation and preeclampsia/eclampsia \[[@ref27]\].

DISORDERS
=========

Given the basic physiological roles of the SLC carriers, it is not surprising that defects in a single carrier lead to a serious disease. The dysfunction of SLCs is associated with countless neurodegenerative disorders (see [Table 1](#T1){ref-type="table"}).

Alzheimer Disease
-----------------

Amyloid-β (Aβ) peptide aggregation or oligomerization, known to be supported in the presence of Zn^2＋^ is one of the reasons affecting the pathogenesis of AD. Zn^2＋^ is transmitted to the brain via SLC39 family carriers. Studies revealed that, the time course expression change of dZip1, an orthologue of human SLC39 family transporter hZIP1 in Drosophila, was recovered in brains of Aβ42 flies when compared with normal control flies. Researchers assume that modulating the expression level of dZip1 may affect the accumulation of Zn^2＋^ in the brain and, accordingly, alter the pathological process of AD \[[@ref44]\]. Recently, it has been determined that hippocampus- dependent learning and memory functions are not only based on synaptic plasticity of glutamatergic synapses, but also inhibitory GABA-secreting interneurons are required \[[@ref45]\]. The closed link between inhibition of learning and memory is also obvious in neurodegenerative disease like Alzheimer's disease mouse model restoring inhibition rescues the associated memory deficits \[[@ref45]\]. Divalent cations play a strong role in the pathogenesis of AD and can also regulate the Ab peptide cluster formation. Proton-divalent cation carriers encoded by SLC11A1 and SLC11A2 are expressed in the brain as well as regulate ion homeostasis from endosomal compartments. SLC11A1 also has pleiotropic effects on pro-inflammatory responses that may be important in AD \[[@ref46]\].

Dementia
--------

Lewy body dementia, the second most common neurodegenerative dementia in the elderly, is characterized by Lewy neurites and Lewy bodies which formed by abnormal a-synuclein accumulation in the brainstem, limbic system, and cortical regions \[[@ref47]\]. Glutamate transporter SLC family 1, member 2 (GLT1/EAAT2) that is expressed in astrocytes, regulates glutamate levels in synapse and plays an important role in the prevention of excitotoxic neuronal damage in certain neurodegenerative diseases. Modified mRNA and/or protein expression in glutamate transporters have been reported in transgenic models of AD \[[@ref47]\]. Neurodegenerative diseases have been suggested to be associated with cellular stress like oxidative stress and endoplasmic reticulum (ER) stress. For instance, the positive immunoreactivity of phosphorylated PERK and eIF2a, modulators of the ER stress response pathway, was observed in the substantia nigra of PD patients \[[@ref7]\]. Accumulation of ER stress or reactive oxygen species causes cell death of dopaminergic neurons. Although SLC30A10 has been shown to play a protective role against oxidative stress, SLC30A10 and cellular stress are thought to be related to neurodegenerative diseases. The mechanism for the cause of neurodegenerative diseases associated with cellular stress and SLC30A10 has not yet been fully elucidated; besides decreased SLC30A10 levels were determined in the brains of AD patients. Although the loss of function of SLC30A10 causes Parkinsonism, the role of SLC30A10 in the cellular cause of ER stress that may be associated with PD is unknown. In a study, the SLC30A10 mutation has been shown to cause Parkinsonism, and an autopsy of the AD patient's brain showed a decrease in SLC30A10 \[[@ref5],[@ref16]\]. On the other hand, oxidative stress or ER stress has been reported to be related to the cause of neurodegenerative disease. In an other study, slc30a10 expression was observed in the cerebral cortex, hippocampus, midbrain, cerebellum and spinal cord of the rat brain. Slc30a10 has also been localized to the dopaminergic neurons of the substantia nigra, glutamatergic neurons of the striatum, and cerebral cortex neurons. Previous studies have demonstrated that the protective role of SLC30A10 against oxidative stress and the relationship between cellular stress and SLC30A10 has not yet been fully elucidated \[[@ref48]\].

Amyotrophic Lateral Sclerosis (ALS)
-----------------------------------

ALS is the most common adult motor neuron disease leading to muscle paralysis and death within 3--5 years of onset. ALS is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the primary motor cortex, brain stem, and spinal cord \[[@ref49]\]. To date, many mechanisms have been described in motor neuron degeneration in ALS. Molecular indicators of glutathione excitotoxicity, impaired axonal transport, oxidative stress, mitochondrial dysfunction, growth factor deficiency, protein aggregation, abnormal RNA metabolism, and apoptosis were observed in the human brain, spinal cord, and transgenic disease models long before the onset of symptoms. Excessive glutamate leading to neuronal degeneration is thought to be one of the pathogenesis of ALS, a fatal neurodegenerative disorder caused by selective death of motor neurons in the brain and spinal cord \[[@ref50],[@ref51]\]. Riluzol, a drug that is used to treat ALS, inhibits the activation of postsynaptic neurons that prevent glutamate release and reduce glutamate-induced sodium ecototoxicity \[[@ref50]\]. Loss of EAAT1 was observed in patients with ALS. Riluzole was found to increase the transport activity of SLC1A3, which takes extracellular glutamate from the synapses and thus reduces glutamate levels in the synaptic cleft \[[@ref52],[@ref53]\]. In another study, riluzole has been shown to stimulate glutamate uptake by increasing the level of SLC1A1 excitatory amino acid carrier in astroglial cells. Similar to EAAT1, EAAT2, the major glutamate carrier in astrocytes, has been reported to reduce the level of glutamate in the synaptic cleft, thereby alleviating excitotoxicity. The neurodegenerative diseases that may benefit from the upregulated EAAT2 function include epilepsy, stroke, and neurotrauma, as well as AD, ALS and PD. All of these diseases have been associated with a decrease in EAAT2 protein expression levels \[[@ref52]-[@ref55]\]. A decrease in glutamate transporter activity has been reported due to decreased GLT1 (EAAT2) isoform in motor and sensory cortex in patients with sporadic ALS \[[@ref9]\]. A decrease in glutamate transporter activity has been reported due to decreased GLT1 (EAAT2) isoform in motor and sensory cortex in patients with sporadic ALS \[[@ref9]\]. For these reasons, the development of a drug that enhances the activity of EAAT2 represents a promising approach to the development of a CNS. According to the mRNA analysis, the previous studies show that the expression of EAAT2 decreased in the spinal cord, motor cortex in ALS's patients \[[@ref56],[@ref57]\]. The SLC25A20, a member of the large mitochondrial carrier family, catalyzes transport through the inner mitochondrial membrane. The production of ATP, calcium homeostasis and the regulation of mitochondria-associated apoptosis are reported in ALS. Abnormalities in the morphology and biochemistry of the cortex, spinal cord and muscles were observed in patients with ALS \[[@ref58]-[@ref60]\].

Huntington Disease
------------------

HD is a deadly neurodegenerative disease that cannot be treated today. Although HD is classically regarded as a motor disorder, it is also characterized by progressive motor coordination disorder and involuntary movements resulting from neurodegeneration of the striatum. HD patients experience cognitive and behavioral disorders such as learning and memory, due to impairment of cortex and hippocampus many years before the onset of motor symptoms. Additionally, similar symptoms are observed in HD mouse models \[[@ref61]\]. While HD patients show hippocampal memory and learning deficits, changes in excitatory synaptic plasticity and spatial cognition in the hippocampus have been reported in HD mouse models \[[@ref62]-[@ref64]\].

Hippocampus excitatory synaptic plasticity changes and degeneration in spatial cognition are reported to occur in HD mouse models \[[@ref65]-[@ref69]\]. Proteomic studies have shown that the gene encoding the KCC2, slc12A5, is highly rich in the Huntington protein (Htt) proteome \[[@ref25],[@ref26]\]. In the mouse study, by using isoform-specific amplification of slc12a5 (KCC2) and slc12a2 (NKCC1), it has been found out that KCC2 protein expression decreased in the hippocampus as it was affected by Htt \[[@ref61]\].

Parkinson's Disease
-------------------

SLC41A1, which has recently been identified as a part of a new PD susceptibility locus named PARK16, has been reported in the pathophysiology of PD, preeclampsia, and nephronophthisis-associated ciliopathies. After that, rare PD-associated coding variants of SLC41A1, ie p.A350V, p.L146G, p.P480P and c.552 ＋ 50G\> A, were identified \[[@ref44]\]. Studies have shown that nigrostriatal dopamine loss is important in the distinctive features of PD. SLC6A3 is known to play an important role in dopamine reuptake in striatal \[[@ref70]\]. Allelic variants in SLC6A3 are located in PD by modulating gene expression and may increase the risk of PD by interacting with the occupational pesticide. SLC6A3/DAT1 genotype has also been found to have a significant effect on fronto-striatal activation and performance in PD. Therefore, SLC6A3 is thought to be associated with PD development by modulating the metabolism of dopamine \[[@ref71]\]. A number of different evidences suggest that the overlapping clinical, genetic, and pathological features of PD, MSA and ALS may be caused by a common potential pathogenic pathway. Firstly, epidemiological studies have indicated that some patients with ALS have parkinsonian symptoms and also the increase in the number of PD patients thought to enhance the risk of developing ALS. Moreover, as ALS and MSA show clinical overlaps, all other evidence suggests that all these diseases occur with the combination of abnormal and improperly folded proteins. Disruption of SLC40A1 mediated Fe^2＋^ flow from neurons is thought to be one of the pathogenesis of PD \[[@ref72]-[@ref74]\]. Disruption of SLC40A1- mediated Fe^2＋^ flow from neurons may also contribute to the pathogenesis of PD \[[@ref75]\].

Depression
----------

Drugs used to treat depression can be classified according to their possible targets. For example, monoamine reuptake inhibitors containing serotonin-selective reuptake inhibitors and noradrenaline reuptake inhibitors inhibit neurotransmitter carriers. Over the past few decades, the development of new antidepressants has been moved from "chance of discovery" to single-targeted strategies and then to multiple target strategies. Several carriers in the SLC6 family have important roles in taking monoamines into the synapses of the CNS. Although they all show overlapping substrate specificity, these include NET (SLC6A2), DAT (SLC6A3), and SERT (SLC6A4), all of which are carriers of noradrenaline, dopamine, and serotonin (also known as 5-hydroxytryptamine). Drug-mediated inhibition of these carriers reduces the clearance of monoamine neurotransmitters from the synapse and thus increases the residence time in the synaptic cleft. As a result, increased concentrations of monoamines in the synaptic cleft increase receptor invasion, leading to increased activation of ligand-gated ion channels and modulation of G-protein-bound receptor signaling. However, the mechanisms by which such drugs ultimately exert antidepressant effects are not yet completely clear \[[@ref21],[@ref76]\]. Glycine has important roles in neuronal inhibition and stimulation in the CNS. It acts as an inhibitor neurotransmitter by activating ionotropic glycine receptors, providing chloride ions to hyperpolarize the postsynaptic membrane. Glycine also binds to excitatory NMDA receptors to provide receptor activation with glutamate. Glycine carriers such as GLYT1 (also known as SLC6A9) and GLYT2 (also known as SLC6A5) on neurons, astrocytes, and glial cells regulate extracellular glycine levels in the brain and thereby regulate NMDA receptor activity \[[@ref77]\].

SLC6A15, a neutral amino acid transporter expressed in neurons, is recommended as a candidate gene for major depression and stress vulnerability with glutamate content, a key neurotransmitter regulating stress response in the hippocampus \[[@ref78]\]. A single nucleotide polymorphism in this gene shows all the markers of altered volume, glutamate levels, and hypothalamus-pituitary- adrenal axis activity and major depression \[[@ref78]\].

In a study of chronic social stress where a conventional slc6a15 knock-out mouse line and a virus-mediated hippocampal slc6a15 overexpression mice were used, both slc-knock-out mice and a virus-mediated hippocampal slc6a15 overexpression mice were reported to have lower anxiety and depressive behaviors compared to stressed wild-type offspring, after chronic social stress. These findings suggest that the deletion of slc6a15 changes the HPA axis activation following chronic social stress and reduces the negative behavioral consequences of chronic social stress. In addition, the expression levels of GluR1 in hippocampus, particularly in dentate gyrus, were reported to be significantly affected by levels of slc6a15. The results of the study showed that slc6a15 levels affect HPA axis activation under chronic stress conditions, regulating anxiety and depressive behaviors and affecting GluR1 expression in hippocampus \[[@ref78]\].

Post-Traumatic Stress Disorder (PTSD)
-------------------------------------

PTSD is a complex disorder characterized by three symptom clusters including re-experiencing, avoidance, and hyperarousal. SLC6A3 (also known as DAT1 or DAT) and it is a biologically relevant candidate gene for PTSD. SLC6A3 encodes a dopamine transporter, a member of the sodium- and chloride-dependent neurotransmitter transporter family, which plays a key role in the regulation of dopaminergic neurotransmission by removing dopamine from the synaptic cleft \[[@ref79]\]. The role of dopamine in the etiology of PTSD is supported by increased urine and plasma dopamine levels. This shows a significant correlation between dopamine concentration and severity of PTSD symptoms. The complexity of the relationship between SLC6A3 and PTSD may be related, not only to genetic but also to the evidence that epigenetic factors constitute the risk of mental illness. Epigenetic disorder plays a role in the pathogenesis of various psychiatric disorders such as depression, schizophrenia, and PTSD. The study investigating how genetic and epigenetic, molecular variation in the SLC6A3 locus affect the risk of PTSD, it has been reported that SLC6A3 39UTR VNTR polymorphism significantly increased the lifetime risk of PTSD. It has also been shown that participants with high DNA methylation provide preventive new evidence for interaction with genetic and epigenetic variation affecting PTSD risk, which significantly increases the risk of the disease. The results of the study support the 9R allele of SLC6A3 39UTR VNTR polymorphism as a risk allele for PTSD compared to homozygous 10R genotype in PTSD \[[@ref80]\].

Schizophrenia
-------------

Glycine has an important role in neuronal inhibition and stimulation in CNS. Glycine binds to excitatory NMDA receptors to provide receptor activation with glutamate. Glycine carriers such as GLYT1 (also known as SLC6A9) and GLYT2 (also known as SLC6A5) on neurons, astrocytes, and glial cells regulate levels of extracellular glycine in the brain and thereby regulate NMDA receptor activity. According to the glutamate hypothesis of schizophrenia, the symptoms of the disease are caused by insufficient glutamatergic (NMDA) signaling and therefore GLYT1 inhibitors have been developed to increase the NMDA signal in this disorder to inhibit glycine reuptake in NMDA receptors and to increase glycine levels \[[@ref2]\].

Epilepsy
--------

Epilepsy is one of the most common neurological disorders in the population up to 1%. It is a complex genetic disease, and many different gene families are actively being investigated as a potential response to antiepileptic drugs. Decreased KCC2 expression in mouse models of intractable epilepsy and in human patients with temporal lobe epilepsy is additional evidence for its role in the regulation of neuronal excitability \[[@ref28]\]. In a study, it has been shown that the synaptic protein SLC10A4 affects the sensitivity to cholinergic chemo-convulsant and the absence of SLC10A4 induces the altered function of neural networks and possibly epileptic vulnerability \[[@ref81],[@ref82]\].

CONCLUSION
==========

In this review, it has been emphasized that SLC proteins are of great importance in the elucidation of neurodegenerative disorder mechanism due to their important role in the synaptic regulation of the neurotransmitters. Therefore, this review will also contribute to the regulation of existing treatments and the creation of new treatment options, with the non-radical treatment of SLC proteins.
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![A schematic representation of the physiologic function of solute carriers (SLCs) and their role in synaptic transmission in the central nervous system. SLC transporters are critical in the termination of synaptic transmission for amino acid neurotransmitters in addition to their role in providing essential nutrients and osmolytes to neurons and glial cells. Dopamine, serotonin, noradrenaline, glycine, and GABA are removed by neurotransmitter sodium symporters. The monoamine transporters (NET, SERT, and DAT) are localized to extra-synaptic sites, whereas GATs, GLYTs, and osmolyte transporter (BGTs), are localized to synaptic and extra-synaptic sites in addition to glial cells. Inhibition of NET, SERT, and DAT transporters by drugs reduces the clearance of neurotransmitters from the synapse, thus increasing their stay time in the synaptic cleft. The resulting increased concentrations of monoamines in the synaptic cleft improve receptor occupancy, leading to increased activation of ligand-gated ion channels. GLTs play a major role in maintaining the extracellular glutamate concentration at low levels and to protect neurons from the excitotoxic action of glutamate. Due to their crucial role in keeping basal concentrations of neurotransmitters low, malfunction, improper, or dysfunction of these transporters may lead to developing neurodegenerative disorders.\
Neurotransmitter transporters (GAT \[g-aminobutyric acid\], GYLT \[glycine\], and monoamine trasporter DAT \[dopamine\], NET \[noradrenaline\], SERT \[serotonin\]). Osmolyte transporter, BGT (betaine). Neutral amino acid transporter, GLT (glutamate).](CPN-18-174-f1){#F1}
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The distribution of solute carrier (SLC) proteins in the brain and the disorders in which play a role

  Gene name   Protein name                           Brain tissue expression                                                                               Disorders
  ----------- -------------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  SLC1                                                                                                                                                     HD, epilepsy, AD, ALS, schizophrenia \[[@ref3]\], dementia
  SLC1A1      EAAC1                                  Neurons \[[@ref9]\]                                                                                   HD, epilepsy, AD \[[@ref9]\]
              EAAT3                                                                                                                                        
  SLC1A2      GLT1                                   Astrocytes \[[@ref9]\]                                                                                AD, PD, ALS \[[@ref9]\], dementia
              EAAT2                                                                                                                                        
  SLC1A3      GLAST                                  Astrocytes, cerebellar Bergmann glia \[[@ref9]\]                                                      AD, HD, ALS, epilepsy \[[@ref9]\]
              EAAT1                                                                                                                                        
  SLC1A4      ASCT1                                  Neurons                                                                                               
              SATT                                                                                                                                         
  SLC1A5      ASCT2                                  Neurons                                                                                               
              AAAT                                                                                                                                         
  SLC1A6      EAAT4                                  Cerebellum (pukinje cells) on postsynaptic dendritis spines \[[@ref9]\]                               
  SLC1A7      EAAT5                                  Retinal neurons                                                                                       
  SLC2A4      GLUT4                                  Hippocampus, neurons                                                                                  Stress \[[@ref7]\]
  SLC5A1      SGLT1                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A2      SGLT2                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A3      SMIT1                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A6      SMVT                                   Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A8      SMCT                                   Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A9      SGLT4                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A10     SGLT5                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A11     SMIT2                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A12     SMCT2                                  Hypothalamic neurons in rat brain \[[@ref82]\]                                                        
  SLC5A4      SGLT3                                  Cholinergic neurons in human brain and hypothalamic neurons in rat brain \[[@ref82]\]                 
  SLC6                                                                                                                                                     Epilepsy \[[@ref21]\], schizophrenia, depression \[[@ref3]\]
  SLC6A1      GAT1                                   Brain                                                                                                 Epilepsy \[[@ref21]\], schizophrenia \[[@ref21]\], anxiety \[[@ref82]\]
  SLC6A2      NET                                    Non adrenergic neuronal somata, axons, dendrites                                                      Depression \[[@ref3],[@ref82]\]
  SLC6A3      DAT                                    Dopaminergic neurons,                                                                                 PD \[[@ref21],[@ref82]\], PTSD \[[@ref79]\], depression \[[@ref3]\]
  SLC6A4      SERT                                   Brain                                                                                                 Anxiety \[[@ref82]\], depression \[[@ref3]\]
  SLC6A5      GLYT2                                  Glycinergic neurons, Golgi cells, brainstem, cerebellum                                               Depression \[[@ref3]\], schizophrenia \[[@ref21]\]
  SLC6A6      TAUT                                   Brain                                                                                                 
  SLC6A7      PROT                                   Glutamatergic neurons, hippocampus                                                                    
  SLC6A8      CT1                                    Ubiquitous all tissues                                                                                
  SLC6A9      GLYT1                                  Brain                                                                                                 Schizophrenia \[[@ref21],[@ref82]\], depression \[[@ref3]\]
  SLC6A11     GAT3                                   Gabaergic neurons, glia                                                                               Epilepsy \[[@ref21]\]
  SLC6A12     BGT1                                   Brain                                                                                                 Epilepsy \[[@ref21]\]
  SLC6A13     GAT2                                   Meninges, ependyma, choroid plexus                                                                    Epilepsy \[[@ref21]\]
  SLC6A15                                            Amygdala, putamen, corpus callosum in human brain and hippocampus in rat brain                        Stress \[[@ref78]\], depression
  SLC6A17                                            Brain                                                                                                 
  SLC6A20                                            Brain                                                                                                 
  SLC7A3      CAT3                                   Neurons \[[@ref22]\]                                                                                  
  SLC7A4      CAT4                                   Brain \[[@ref22]\]                                                                                    
  SLC7A5      LAT2                                   Brain \[[@ref22]\]                                                                                    
  SLC7A6      yLAT                                   Brain \[[@ref22]\]                                                                                    
  SLC7A8      LAT2                                   Brain \[[@ref22]\]                                                                                    
  SLC7A10     ASC1                                   Brain \[[@ref22]\]                                                                                    
  SLC7A11     xCT                                    Brain \[[@ref22]\]                                                                                    
  SLC8A1      NCX1                                   Specific splice variants found in brain                                                               
  SLC8A2      NCX2                                   Abundant in neurons in all parts of the brain                                                         
  SLC8A3      NCX3                                   At lower levels in some brain regions                                                                 
  SLC10A4     P4                                     Cholinergic neurons                                                                                   AD, epilepsy \[[@ref3]\]
  SLC11A1     NRAMP1                                                                                                                                       AD, PD \[[@ref3]\]
  SLC11A2     DMT1                                                                                                                                         PD \[[@ref3]\]
  SLC12A2     NKCC1                                  Ubiquitous in all tissues \[[@ref28]\]                                                                Epilepsy \[[@ref3]\], HD
  SLC12A4     KCC1                                   Ubiquitous in all tissues \[[@ref28]\]                                                                
  SLC12A5     KCC2                                   Neurons \[[@ref28]\]                                                                                  Epilepsy \[[@ref3]\], HD
  SLC12A7     KCC4                                   Extensive limited in brain \[[@ref28]\]                                                               Epilepsy \[[@ref3]\]
  SLC13A3     NaC3                                   Brain                                                                                                 
  SLC13A5     NaC2                                   Brain                                                                                                 
  SLC15A3     PHT2                                   Brain                                                                                                 
  SLC15A4     PHT1                                   Brain                                                                                                 
  SLC16A2     MCT8                                   Brain                                                                                                 
  SLC16A5     MCT6                                   Brain                                                                                                 
  SLC16A7     MCT2                                   Brain                                                                                                 
  SLC16A9     MCT9                                   Brain                                                                                                 
  SLC16A14    MCT14                                  Brain                                                                                                 
  SLC17A2     NPT3                                   Brain                                                                                                 
  SLC17A6     VGLUT2                                 Neurons                                                                                               
  SLC17A7     VGLUT1                                 Neurons                                                                                               
  SLC17A8     VGLUT3                                 Neurons, glia                                                                                         
  SLC17A9     VNUT                                   Neurons                                                                                               
  SLC18A2     VMAT2                                  All CNS aminergic neurons                                                                             
  SLC18A3     VAChT                                  Cholinergic neurons                                                                                   
  SLC18B1     C6orf192                               Brain                                                                                                 
  SLCO1A2     OATP1A2                                Brain                                                                                                 
  SLCO1C1     OATP1C1                                Blood-brain barrier                                                                                   
  SLC22A1     OCT1                                   Blood-brain barrier                                                                                   
  SLC22A2     OCT2                                   Blood-brain barrier, neurons                                                                          
  SLC22A3     OCT3                                   Neurons, glial cells, plexus choroideus                                                               
  SLC22A15    FLIPT1                                 Brain                                                                                                 
  SLC22A17    BOIT                                   Brain                                                                                                 
  SLC22B1     SV2A                                   Subcortex (basal ganglia, thalamus)                                                                   
  SLC22B2     SV2B                                   Hippocampus, cortex                                                                                   
  SLC22B3     SV2C                                   Striatum, substantia nigra, pons/medulla oblongata, olfactory bulb                                    
  SLC22B4     SVOP                                   Brain                                                                                                 
  SLC22B 5    SVOPL                                  Brain                                                                                                 
  SLC23A2     SVCT2                                  Neurons                                                                                               
  SLC24A2     NCKX2                                  Brain                                                                                                 
  SLC24A3     NCKX3                                  Brain                                                                                                 
  SLC24A4     NCKX4                                  Brain                                                                                                 
  SLC25                                                                                                                                                    Epileptic encephalopathy \[[@ref3]\]
  SLC25A2     ORC2[a](#t1fn3){ref-type="table-fn"}   Brain                                                                                                 
  SLC25A3     PHC                                    Brain                                                                                                 
  SLC25A4     ANT1                                   Brain                                                                                                 
  SLC25A5     ANT2                                   Brain                                                                                                 
  SLC25A6     ANT3                                   Brain                                                                                                 
  SLC25A8     UCP2                                   Hypothalamus, pituitary, brainstem \[[@ref33]\]                                                       
  SLC25A10    DIC                                                                                                                                          
  SLC25A12    AGC1                                                                                                                                         
  SLC25A14    UCP5                                   Hypothalamus, hippocampus, thalamus, amygdale in the mice brain \[[@ref33]\]                          
              BMCP1                                                                                                                                        
  SLC25A15    ORC1                                   Brain                                                                                                 
                                                     Brain                                                                                                 
  SLC25A18    GC2                                    Brain                                                                                                 
  SLC25A19    DNC                                    Brain                                                                                                 
  SLC25A20    CAC                                    Brain                                                                                                 ALS
  SLC25A22    GC1                                    Brain                                                                                                 
  SLC25A23    APC2                                   Brain                                                                                                 
  SLC25A25    APC3                                   Brain                                                                                                 
  SLC25A27    UCP4                                   Brain                                                                                                 
  SLC25A33                                           Brainstem, thalamus, corpus callosum, hippocampus brainstem, thalamus in the rat brain \[[@ref33]\]   
  SLC25A40                                           Cerebellum, olfactory bulb, cerebral cortex, midbrain, pons \[[@ref33]\]                              
  SLC25A41    APC4                                   Olfactory bulb, pons, midbrain, cerebellum \[[@ref33]\]                                               
  SLC25A42                                           Pons, midbrain, thalamus \[[@ref33]\]                                                                 
  SLC25A44                                           Hindbrain, cerebellum, pons, midbrain, hypothalamus, corpus callosum \[[@ref33]\]                     
  SLC25A46                                           Hindbrain, cerebellum, pons, midbrain, hypothalamus, corpus callosum \[[@ref33]\]                     
  SLC26A9     SLC26A9                                Brain                                                                                                 
  SLC26A11    SUT1                                   Brain                                                                                                 
  SLC27A1     FATP1                                  Brain                                                                                                 
  SLC27A4     FATP4                                  Brain                                                                                                 
  SLC28A2     CNT2                                   Brain                                                                                                 
  SLC29A4     ENT4                                   Brain                                                                                                 
  SLC30A3                                            Brain                                                                                                 
  SLC30A4                                            Brain                                                                                                 
  SLC30A10                                           Brain                                                                                                 Dementia \[[@ref5],[@ref48]\], PD, AD \[[@ref16]\]
  SLC31                                              Brain                                                                                                 Degenerative neuronal disease \[[@ref3]\]
  SLC33A1     CTR1                                   Brain                                                                                                 
  SLC35F3                                            Cerebellum                                                                                            
  SLC35F4                                            Cerebellum                                                                                            
  SLC36A1     PAT1                                   Brain                                                                                                 
  SLC37A3     SPX3                                   Brain                                                                                                 
  SLC38A1     SNAT1                                  Brain                                                                                                 
  SLC38A4     SNAT4                                  Brain                                                                                                 
  SLC38A5     SNAT5                                  Brain                                                                                                 
  SLC38A6     SNAT6                                  Brain                                                                                                 
  SLC38A7     SNAT7                                  Brain                                                                                                 
  SLC38A8     SNAT8                                  Brain                                                                                                 
  SLC38A10    N/A                                    Brain                                                                                                 
  SLC39                                                                                                                                                    Neurodegeneration \[[@ref3]\], PD, AD
  SLC39A4     ZIP4                                   Hippocampus, neurons                                                                                  
  SLC39A10    ZIP10                                  Brain                                                                                                 
  SLC39A12    ZIP1                                   Brain                                                                                                 
  SLC40A1     FPN1                                                                                                                                         PD
  SCL41A2     RhBG                                   Cerebellum                                                                                            PD
  SLC44A1     CTL1                                   Brain                                                                                                 
  SLC44A5     CTL5                                   Brain                                                                                                 
  SLC45A1     SLC45A1                                Brain                                                                                                 
  SLC45A4     SLC45A4                                Brain                                                                                                 
  SLC49A1     FLVCR1                                 Brain                                                                                                 
  SLC49A2     FLVCR2                                 Brain                                                                                                 
  SLC49A3     MFSD7                                  Brain                                                                                                 
  SLC52A2                                            Brain                                                                                                 
  SLC56A4     SFXN4                                  Brain                                                                                                 
  SLC56A5     SFXN5                                  Brain                                                                                                 
  SLC57                                              Brain                                                                                                 ALS \[[@ref3]\]
  SLC57A1     NIPA1                                  Brain                                                                                                 
  SLC59A1     MFSD2A                                 Brain                                                                                                 
  SLC60A2     MFSD4B                                 Brain                                                                                                 
  SLC61A1     NPC1                                   Cortex, hypothalamus, cerebellum                                                                      

EAAC, excitatory amino acid carrier; EAAT, excitatory amino acid transporter; ASCT, amino acid transporter; DAT, dopamine transporter; PHT, phosphate transporter; GAT, GABA transporter; GLT, glutamate transporter; GLYT, glycine transporters; MCT, monocarboxylate transporter; NCX, Na^＋^/Ca^2＋^; NET, noradrenaline transporter; NRAMP, natural resistance-associated macrophage protein; OATP, organic anion transporter; SERT, serotonin transporter; SGLT, sodium glucose cotransporter 2 (SGLT-2); Zip, zinc transporter; ALS, amyotrophic lateral sclerosis; PD, Parkinson's disease; HD, Huntington disease; AD, Alzheimer disease.

Empty areas show that there is no study about the SCL protein.

Ornithine carrier.
